Please Wait.....
Report
Biological Therapies for Cancer: Technologies and Global Markets
Market Research Report I 2025-11-03 I 139 Pages I BCC Research
Description
Report Scope
This report provides an overview of the global biological therapies for the cancer market and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030. The market is based on technology, application, end user, and region. The regions covered in this study include North America, Europe, Asia-Pacific, the Rest of the World, focusing on major countries in these regions.
The report also sheds light on developments related to venture capital and corporate investments, regulatory trends, and the enterprise strategies of key firms as well as potential future opportunities stemming from biological therapies for cancer of precision medicine and population genomics programs. The combination of in-depth market forecasts, macroeconomic analysis, and tariff assessments makes this report a critical resource for stakeholders, investors, and policymakers seeking to understand and take advantage of the rapidly developing biological therapies for cancer sector. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also analyzes emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape, which provides the ranking/share of key players in the biological therapies for cancer market. It also has a dedicated section of company profiles that covers the details of key market players. For market estimates, data have been provided for 2022 and 2023 as the historic years, 2024 as the base year, and 2025-2030 for the forecast years.
Report Includes
- 43 data tables and 53 additional tables
- An analysis of the global markets for biological therapies for cancer treatment and related technologies
- Analyses of the global market trends, with revenue data for 2022-2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) through 2030
- Estimates of the current market size and revenue prospects for the global cancer biologics market, along with a market share analysis by product type, cancer type, and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
- Impact analysis of the U.S. tariff laws on the market
- Insights derived from Porter's Five Forces model, as well as global supply chain
- A look at major issues and trends related to the R&D of more effective cancer treatment, new cancer therapeutics in development and the outlook on cancer clinical trials
- Key marketed drugs and recent approvals, sales statistics and past performance of the top-selling biologics and insight into their patent expiries
- A relevant patent analysis, featuring key granted and published patents
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Merck & Co. Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., AstraZeneca, and Johnson & Johnson
Executive Summary
Summary:
The global biological therapies market for cancer is expected to grow from $157 billion in 2025 and is projected to reach $225 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025 to 2030.
The biological therapies for cancer market has experienced rapid growth, driven by increasing adoption of targeted and immuno-oncology therapies across multiple tumor types. Rising demand for precision medicine is a key growth factor, as clinicians and healthcare systems prioritize treatments tailored to the molecular and immunological profile of individual patients. Advances in monoclonal antibodies, immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates (ADCs) are expanding the range of effective treatment options and enabling more durable clinical responses.
Major global players, including Merck & Co., Bristol-Myers Squibb, F. Hoffmann-La Roche, AstraZeneca, Johnson & Johnson, and Novartis, are driving innovation through pipeline expansion, clinical trial programs, and strategic collaborations with hospitals, research institutions, and biotechnology companies. In addition, partnerships between pharmaceutical companies, academic research centers, and government-funded initiatives are accelerating access to cutting-edge biologics and fostering the development of combination therapies.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Technological Advances
Market Dynamics and Growth Factors
Segmental Analysis
Conclusion
Chapter 2 Market Overview
Overview and Market Definition
Key Modalities and Mechanisms of Action
Porter's Five Forces Model
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Competition in the Industry
Threat of Substitutes
Macroeconomic Factors Analysis
Aging Population Driving Cancer Incidence and Demand for Biologics
Rising Healthcare Expenditures and Oncology Drug Spending
Impact of the U.S. Tariff Scenario
Pricing Strategies for Cancer Biologics
Value-Based Pricing
Premium Pricing for Innovation
Indication-Based Pricing
Market Access and Tiered Pricing
Competitive Benchmarking
Cancer Drug Costs
Overview of Biosimilars
Biosimilars and Costs of Cancer Drugs
Biosimilars in India and China
Biosimilars in Europe
Issues with Biosimilars
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Global Cancer Incidence
Advances in Immuno-Oncology and Targeted Therapies
Shift Towards Personalized and Precision Medicine
Market Restraints
High Treatment Costs
Stringent Manufacturing and Regulatory Requirements
Market Opportunities
Expanding Indications for Approved Biologics
Technological Advances in Biologics Manufacturing
Chapter 4 Regulatory Landscape
Biological Therapies for Cancer Industry Regulatory Scenario
Overview
U.S.
EU
Japan
China
India
Medicare Coverage and Reimbursement for Cancer Care
Chapter 5 Emerging Technologies and Developments
Overview
Next-Generation Antibody-Drug Conjugates (ADCs)
Bispecific and Multispecific Antibodies
Neoantigen and Personalized Cancer Vaccines (mRNA and Peptide)
Allogeneic ("Off-the-Shelf") Cell Therapies
Artificial Intelligence (AI) in Biological Cancer Therapies
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis for Biological Therapies for Cancer by Product Type
Monoclonal Antibodies
Vaccines
CAR T-cell Therapy
Cancer Growth Blockers
Immune Checkpoint Inhibitors
Other (Blood Cell Growth Factors, Cytokines)
Market Analysis of Biological Therapies for Cancer by Cancer Type
Epidemiology by Cancer Type/Site
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Other (Blood, Skin, Ovarian, Rare Cancer)
Geographic Breakdown
Global Biosimilars Market by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Cancer Clinical Trials and Biologics in Development
Overview
Key Pipeline Drugs by Company
Chapter 8 Competitive Landscape
Overview
Biological Therapy for Cancer Market: Major Players
Chapter 9 Appendix
Methodology
References
Abbreviations
Company Profiles
AMGEN INC.
ASTRAZENECA
BAYER AG
BIONTECH SE
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC
INCYTE
INNATE PHARMA INC.
JOHNSON & JOHNSON
LILLY USA LLC
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI
List of Tables
Summary Table : Global Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 1 : Key Federal Health Insurance Programs in the U.S.
Table 2 : Global Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 3 : Monoclonal Antibodies Approved for Oncology
Table 4 : Global Monoclonal Antibodies Therapy Market for Cancer, by Region, Through 2030
Table 5 : Global Vaccines Therapy Market for Cancer, by Region, Through 2030
Table 6 : Global CAR T-Cell Therapy Market for Cancer, by Region, Through 2030
Table 7 : Global Cancer Growth Blockers Therapy Market for Cancer, by Region, Through 2030
Table 8 : Immune Checkpoint Inhibitors Approved for Oncology
Table 9 : Global Immune Checkpoint Inhibitors Therapy Market for Cancer, by Region, Through 2030
Table 10 : Global Other Biological Therapies Market for Cancer, by Region, Through 2030
Table 11 : Global Cancer Incidence, by Cancer Type/Site, 2022
Table 12 : Global Biological Therapies Market for Cancer, by Cancer Type, Through 2030
Table 13 : Global Biological Therapies Market for Lung Cancer, by Region, Through 2030
Table 14 : Global Biological Therapies Market for Breast Cancer, by Region, Through 2030
Table 15 : Global Biological Therapies Market for Colorectal Cancer, by Region, Through 2030
Table 16 : Global Biological Therapies Market for Prostate Cancer, by Region, Through 2030
Table 17 : Global Biological Therapies Market for Other (Blood, Skin, Ovarian, Rare Cancers) Cancers, by Region, Through 2030
Table 18 : Global Biological Therapies Market for Cancer, by Region, Through 2030
Table 19 : North American Biological Therapies Market for Cancer, by Country, Through 2030
Table 20 : North American Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 21 : North American Biological Therapies Market for Cancer, by Cancer Type, Through 2030
Table 22 : European Biological Therapies Market for Cancer, by Country, Through 2030
Table 23 : European Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 24 : European Biological Therapies Market for Cancer, by Cancer Type, Through 2030
Table 25 : Asia-Pacific Biological Therapies Market for Cancer, by Country, Through 2030
Table 26 : Asia-Pacific Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 27 : Asia-Pacific Biological Therapies Market for Cancer, by Cancer Type, Through 2030
Table 28 : Rest of the World Biological Therapies Market for Cancer, by Product Type, Through 2030
Table 29 : Rest of the World Biological Therapies Market for Cancer, by Cancer Type, Through 2030
Table 30 : Clinical Trials, by Cancer Type/Site and Phase, 2025
Table 31 : Key Pipeline Cancer Biologics
Table 32 : Sales of Blockbuster Biological Cancer Therapy Drugs, 2024
Table 33 : Leading Biological Therapies for Cancer Companies, Strategic Developments, 2024-2025
Table 34 : Information Sources for this Report
Table 35 : Abbreviations Used in this Report
Table 36 : Amgen Inc.: Company Snapshot
Table 37 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 38 : Amgen Inc.: Product Portfolio
Table 39 : Amgen Inc.: News/Key Developments, 2024-2025
Table 40 : AstraZeneca: Company Snapshot
Table 41 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 42 : AstraZeneca: Product Portfolio
Table 43 : AstraZeneca: News/Key Developments, 2024-2025
Table 44 : Bayer AG: Company Snapshot
Table 45 : Bayer AG: Financial Performance, FY 2023 and 2024
Table 46 : Bayer AG: Product Portfolio
Table 47 : Bayer AG: News/Key Developments, 2024
Table 48 : BioNTech SE: Company Snapshot
Table 49 : BioNTech SE: Financial Performance, FY 2023 and 2024
Table 50 : BioNTech SE: Product Portfolio
Table 51 : BioNTech SE: News/Key Developments, 2024-2025
Table 52 : Bristol-Myers Squibb Co.: Company Snapshot
Table 53 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 54 : Bristol-Myers Squibb Co.: Product Portfolio
Table 55 : Bristol-Myers Squibb Co.: News/Key Developments, 2024-2025
Table 56 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 57 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 58 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 59 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024-2025
Table 60 : Gsk Plc: Company Snapshot
Table 61 : Gsk Plc: Financial Performance, FY 2023 and 2024
Table 62 : Gsk Plc.: Product Portfolio
Table 63 : Gsk Plc.: News/Key Developments, 2024-2025
Table 64 : Incyte: Company Snapshot
Table 65 : Incyte: Financial Performance, FY 2023 and 2024
Table 66 : Incyte: Product Portfolio
Table 67 : Incyte: News/Key Developments, 2025
Table 68 : Innate Pharma Inc.: Company Snapshot
Table 69 : Innate Pharma Inc.: Financial Performance, FY 2023 and 2024
Table 70 : Innate Pharma Inc.: Product Portfolio
Table 71 : Innate Pharma Inc.: News/Key Developments, 2024-2025
Table 72 : Johnson & Johnson: Company Snapshot
Table 73 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 74 : Johnson & Johnson: Product Portfolio
Table 75 : Johnson & Johnson: News/Key Developments, 2025
Table 76 : Lilly USA LLC: Company Snapshot
Table 77 : Lilly USA LLC: Financial Performance, FY 2023 and 2024
Table 78 : Lilly USA LLC: Product Portfolio
Table 79 : Lilly USA LLC: News/Key Developments, 2023-2024
Table 80 : Merck & Co. Inc.: Company Snapshot
Table 81 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 82 : Merck & Co. Inc.: Product Portfolio
Table 83 : Merck & Co. Inc.: News/Key Developments, 2024-2025
Table 84 : Novartis AG: Company Snapshot
Table 85 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 86 : Novartis AG: Product Portfolio
Table 87 : Novartis AG: News/Key Developments, 2024-2025
Table 88 : Pfizer Inc.: Company Snapshot
Table 89 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 90 : Pfizer Inc.: Product Portfolio
Table 91 : Pfizer Inc.: News/Key Developments, 2025
Table 92 : Sanofi: Company Snapshot
Table 93 : Sanofi: Financial Performance, FY 2023 and 2024
Table 94 : Sanofi: Product Portfolio
Table 95 : Sanofi: News/Key Developments, 2024-2025
List of Figures
Summary Figure : Global Biological Therapies Market Shares for Cancer, by Product Type, 2024
Figure 1 : Porter's Five Forces Analysis for the Biological Therapies for Cancer Market
Figure 2 : Snapshot of the Market Dynamics for Biological Therapies for Cancer
Figure 3 : Global Biological Therapies Market Shares for Cancer, by Product Type, 2024
Figure 4 : Global Cancer Incidence in Males, by Type/Site, 2022
Figure 5 : Global Cancer Incidence in Females, by Type/Site, 2022
Figure 6 : Global Cancer Incidence, by Region, 2022
Figure 7 : Global Biological Therapies Market Shares for Cancer, by Cancer Type, 2024
Figure 8 : Global Biological Therapies Market Shares for Cancer, by Region, 2024
Figure 9 : North American Biological Therapies Market Shares for Cancer, by Country, 2024
Figure 10 : European Biological Therapies Market Shares for Cancer, by Country, 2024
Figure 11 : Asia-Pacific Biological Therapies Market Shares for Cancer, by Country, 2024
Figure 12 : Global Biological Therapy Market Shares for Cancer, by Key Manufacturers and Suppliers, 2024
Figure 13 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 14 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 15 : Astrazeneca: Revenue Shares, by Business Unit, FY 2024
Figure 16 : Astrazeneca: Revenue Shares, by Country/Region, FY 2024
Figure 17 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
Figure 18 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
Figure 19 : BioNTech SE: Revenue Shares, by Country/Region, FY 2024
Figure 20 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 21 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 22 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 23 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 24 : Gsk Plc: Revenue Shares, by Business Unit, FY 2024
Figure 25 : Gsk Plc: Revenue Shares, by Country/Region, FY 2024
Figure 26 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
Figure 27 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
Figure 28 : Lilly USA LLC: Revenue Shares, by Country/Region, FY 2024
Figure 29 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 30 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 31 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 32 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 33 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 34 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 35 : Sanofi: Revenue Shares, by Country/Region, FY 2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security